Uncategorized
Tesla gambles on ‘black box’ AI tech for robotaxis
By Norihiko Shirouzu and Chris Kirkham (Reuters) – Tesla aims to stun investors Thursday night with its long-awaited “robotaxi unveil,”…
Month: October 2024
S&P 500 earnings to put investor focus on tech, AI
By Caroline Valetkevitch NEW YORK (Reuters) – Investors will be looking for evidence that investment in artificial intelligence among S&P…
Uncategorized
Monstrous Hurricane Milton targets Florida, triggering evacuations from storm-weary coast
By Julio-Cesar Chavez and Octavio Jones TAMPA (Reuters) -An expanding Hurricane Milton churned toward Florida’s battered Gulf Coast on Tuesday,…
Uncategorized
TikTok sued by 13 states and DC, accused of harming younger users
By Jody Godoy and David Shepardson NEW YORK/WASHINGTON (Reuters) – TikTok faces new lawsuits filed by 13 U.S. states and…
Uncategorized
Berkshire Hathaway nets $10 billion from BofA share-sale spree
By Niket Nishant and Manya Saini (Reuters) – Warren Buffett-led Berkshire Hathaway further cut its stake in Bank of America,…
Uncategorized
Boeing weighs options for raising cash as ratings downgrade looms, sources say
By Shankar Ramakrishnan, Allison Lampert, Echo Wang and Mike Stone NEW YORK (Reuters) – Boeing is examining options to raise…
India, US to cooperate on critical battery minerals, trade minister says
WASHINGTON (Reuters) – Indian Trade Minister Piyush Goyal said on Thursday that he has executed an agreement with U.S. Commerce…
Uncategorized
US port strike disrupts hamburger supplies, frozen seafood
By Tom Polansek and P.J. Huffstutter CHICAGO (Reuters) – Dockworkers striking at U.S. East Coast and Gulf Coast ports are…
Uncategorized
Oil jumps over $3 a barrel as Middle East conflict stokes supply worry
By Georgina McCartney HOUSTON (Reuters) -Oil prices surged on Thursday as concerns mounted that a widening regional conflict in the…
US Medicare issues updated rules for second round of drug negotiations
By Ahmed Aboulenein WASHINGTON (Reuters) – The U.S. government will provide more time for negotiations and more chances for drugmakers…